The US Food and Drug Administration (FDA) recently released another <a href= "https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm" target= "_blank" rel="noopener">warning for fluoroquinolones, this time regarding aortic dissection and aneurysm.</a>  We review the evidence behind this warning, including the following studies: Lee CC  <a href= "https://www.ncbi.nlm.nih.gov/pubmed/26436523" target="_blank" rel= "noopener">Risk of Aortic Dissection and Aortic Aneurysm in Patients Taking Oral Fluoroquinolone</a>. JAMA Intern Med. 2015;175(11):1839-47. Lee CC <a href= "https://www.ncbi.nlm.nih.gov/pubmed/30213330" target="_blank" rel= "noopener">Oral Fluoroquinolone and the Risk of Aortic Dissection. J Am Coll Cardiol.</a> 2018;72(12):1369-1378. Pasternak B <a href= "https://www.ncbi.nlm.nih.gov/pubmed/29519881" target="_blank" rel= "noopener">Fluoroquinolone use and risk of</a> aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678. We then review the <a href= "Clinical%20Policy:%20Critical%20Issues%20in%20the%20Evaluation%20and%20Management%20of%20Adult%20Patients%20With%20Suspected%20Acute%20Nontraumatic%20Thoracic%20Aortic%20Dissection.%20Ann%20Emerg%20Med.%202015;%2065(1)"> ACEP clinical policy on aortic dissection</a> covering risk scores, d-dimers, and management of aortic dissection Thanks for listening! Jeremy Faust and Lauren Westafer

Supraventricular Tachycardia Treatment Controversies

We  believe in the educational merits of Free Open Access Medical education (FOAM), which includes podcasts, blogs, articles on PubMed Central, conferences streamed for free and more.  As a result, we would like to encourage others to move beyond quoting podcasts and into the realm of tying “cutting edge” FOAM to the core content.  We’ll provide some review and references for listeners to go read.  Why, indeed, should we FOAM it alone when FOAM can inspire us to go, read, think, and be excellent?